[A21-137] Albutrepenonacog alfa (haemophilia B) - Assessment according to §35a Social Code Book V
Last updated 17.01.2022
Project no.:
A21-137
Commission:
Commission awarded on 15.10.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Haematology
Indication:
Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency)
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.